A major Swiss pharmaceutical company is maintaining its commitment to a substantial German investment even as industry rivals retreat from the country due to government policy concerns.
Roche confirmed to Reuters that it will proceed with its €600 million ($692.88 million) project to build a new diagnostic manufacturing facility in Penzberg, Germany, despite recent moves by competitors to reduce their German investments.
The commitment stands in contrast to recent decisions by other pharmaceutical companies. Eli Lilly announced it would cut its German investment from $2.3 billion to half that amount, while German pharmaceutical company Boehringer Ingelberg abandoned its €900 million investment plans entirely. Both companies pointed to the German government’s proposed healthcare cost reduction policies as the reason for their decisions.
However, Roche indicated it will need to take a more cautious approach to future German investments moving forward.
The Penzberg project represents Roche’s most significant single investment in Germany, with planning that began several years ago and construction scheduled for completion by 2027. Daniel Steiners, CEO of Roche Pharma AG, expressed concerns about the policy environment in an interview with Reuters.
“The cabinet decision is creating a new degree of uncertainty regarding investments, research, and production decisions in Germany,” Steiners stated.
Steiners warned that the government’s approach could result in substantial economic harm while providing little advantage for creating a sustainable healthcare system. He suggested that the legislative process still presents an opportunity to maintain Germany’s position as a dependable investment destination.
